Literature DB >> 9874852

The diagnosis and management of neurofibromatosis 2 in childhood.

M MacCollin1, V F Mautner.   

Abstract

Neurofibromatosis 2 (NF2) is an autosomal-dominant condition that causes multiple benign nervous system tumors, especially vestibular schwannoma. Although frequently confused with the more common neurofibromatosis 1, NF2 presents a distinct set of diagnostic, genetic, and management issues. The presentation and natural history of NF2 differs in children and adults, with eighth nerve dysfunction often overshadowed by the effects of other tumors on the nervous system. Molecular diagnostics is an important tool for early recognition of NF2, and when performed in the context of appropriate counseling and follow-up, may lead to a better final outcome of the disease. Further research into the molecular genetic etiology of NF2 promises to broaden the possibilities of therapy for this devastating disorder.

Entities:  

Mesh:

Year:  1998        PMID: 9874852     DOI: 10.1016/s1071-9091(98)80003-x

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  12 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

2.  Clinicopathologic assay of 15 tumor resections in a family with neurofibromatosis type 2.

Authors:  Salvatore Di Maio; Goran Mrak; Gordana Juric-Sekhar; Donald Born; Alessandra Mantovani; Laligam N Sekhar
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

3.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

Review 4.  Molecular pathogenesis of astrocytic tumours.

Authors:  Koichi Ichimura; Hiroko Ohgaki; Paul Kleihues; V Peter Collins
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

5.  Dermatologic manifestations in paediatric neurofibromatosis type 2: a cross sectional descriptive multicentric study.

Authors:  S Legoupil; D Bessis; F Picard; S Mallet; J Mazereeuw; A Phan; D Dupin-Deguine; M Kalamarides; C Chiaverini
Journal:  Orphanet J Rare Dis       Date:  2022-06-21       Impact factor: 4.303

6.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

7.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 8.  Natural history of neurofibromatosis type 2 with onset before the age of 1 year.

Authors:  Martino Ruggieri; Anna Lia Gabriele; Agata Polizzi; Vincenzo Salpietro; Francesco Nicita; Piero Pavone; Nunzio Platania; Pietro Milone; Angela Distefano; Giuseppe Privitera; Giuseppe Belfiore; Francesca Granata; Rosario Caltabiano; Vincenzo Albanese; Lorenzo Pavone; Aldo Quattrone
Journal:  Neurogenetics       Date:  2013-02-03       Impact factor: 2.660

9.  Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy.

Authors:  Teresa Stachowicz-Stencel; Anna Synakiewicz; Ewa Bien; Elzbieta Adamkiewicz-Drozynska; Miroslawa Wybieralska-Dubaniewicz; Anna Balcerska
Journal:  Childs Nerv Syst       Date:  2010-07-27       Impact factor: 1.475

Review 10.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.